Congenital brain anomalies cause a spectrum of neurologic deficits; although some may be barely noticeable, others may be fatal.
Some of the most serious neurologic anomalies (eg, anencephaly, encephalocele, spina bifida) develop in the first 2 months of gestation and represent defects in neural tube formation (dysraphism). Others, such as lissencephaly, result from problems with neuronal migration (see Malformed Cerebral Hemispheres), which occurs between 9 weeks and 24 weeks of gestation. Hydranencephaly and porencephaly are secondary to destructive processes that occur after the basic architecture of the brain has formed. Some anomalies (eg, meningocele) may be relatively benign.
There are many causes of congenital brain anomalies, including many previously unknown genetic factors. Next-generation sequencing techniques, such as genetic panels and whole exome sequencing, have revealed a large number of genetic causes of these anomalies.
Ultrasonography can be used to accurately screen for many malformations in utero. Newer fetal MRI techniques are increasingly useful, mainly when ultrasound findings are of concern. Amniocentesis can be used to find larger chromosomal rearrangements and breakage but often misses more subtle genetic causes of congenital anomalies.
Parents often need psychologic support when a malformation is detected and also genetic counseling, because the risk of having a subsequent child with such a malformation may be high.
Prevention of Congenital Neurologic Anomalies
Women who have had a fetus or infant with a neural tube defect are at high risk and should take folate
All women of childbearing age who have not had a fetus or infant with a neural tube defect should consume at least 400 mcg/day of folate through diet or by taking a supplement (some experts recommend 800 mcg/day to further reduce risk) and continue doing so through the 1st trimester. Although folate supplementation reduces the risk of having a child with a neural tube defect, risk reduction is less than in women who previously had a fetus or infant with a neural tube defect (ie, risk reduction is < 75%).
